With a market cap of only $225 million (including $43 million in cash as of June 30th), Compugen Ltd. (CGEN) has the potential to deliver outsized returns for shareholders over the next 12 to 24 months.
Since publishing my initial article on Compugen on SA on February 20, 2018, Compugen has had a transformative year as it transitions into a clinical stage company, and provides further evidence of the power and effectiveness of its computational predictive discovery capabilities.
Compugen's Computational Predictive Discovery Methods May Revolutionize the Drug Discovery Process
Compugen Ltd. (with the